FDA Approves GADOTERIDOL — Slate Run Pharmaceuticals, LLC
Slate Run Pharmaceuticals has been granted FDA approval for its intravenous gadoteridol injection, granting the company access to the commercial market for this diagnostic imaging agent. This approval significantly expands Slate Run’s portfolio, allowing the company to better compete for market share in the rapidly growing diagnostic contrast media sector.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
START FREE — 10,000 calls/day, no key needed